MUC16 expression in pre and post-treatment groups using both drugs (methotrexate and cisplatin) was up-regulated and displayed an increasing trend in the placebo (4.31–5.11%), AF(D)NMs (6.13–6.36%) and IV-drug groups (7.67–8.14%) (p < 0.05), whilst in the NMs (D) group, MUC16 expression was down-regulated (2.67–3.3%) (Figure 11). Here, MUC16 is linked to atrial fibrillation.